Table 2 Comparison of the condition and drug treatment between the cSLE and aSLE groups during pregnancy
Condition or drug treatment | cSLE (N = 22) | aSLE (N = 145) | P value |
|---|---|---|---|
Active SLE (SLEPDAI > 4) | 12 (54.5%) | 30 (20.7%) | 0.001 |
   Active with active LN | 11/12 (91.7%) | 20/30 (66.7%) | 0.202 |
Mucocutaneous disorders | 3 (13.6%) | 31 (21.4%) | 0.578 |
Musculoskeletal disorders | 1 (4.5%) | 7 (4.8%) | 1.000 |
Cardiopulmonary disorders | 2 (9.1%) | 24 (16.6%) | 0.559 |
Liver dysfunction | 0 (0.0%) | 8 (5.5%) | 0.553 |
Neuropsychiatric disorders | 0 (0.0%) | 2 (1.4%) | 1.000 |
Haematologic disorders | 5 (22.7%) | 49 (33.8%) | 0.301 |
Active LN | 11 (50.0%) | 26 (17.9%) | 0.001 |
Antiphospholipid syndrome | 0 (0.0%) | 8 (5.5%) | 0.553 |
Sjogren’s syndrome | 0 (0.0%) | 7 (4.8%) | 0.596 |
Positive ANA Ab | 14 (63.6%) | 121 (83.4%) | 0.056 |
Positive anti-dsDNA Ab | 14 (63.6%) | 53 (36.6%) | 0.016 |
Positive anti-Sm Ab | 0 (0.0%) | 25 (17.2%) | 0.073 |
Positive anti-RNP Ab | 5 (22.7%) | 55 (37.9%) | 0.166 |
Positive anti-SSA/Ro Ab | 9 (45.0%) | 88 (67.7%) | 0.048 |
 Missing | 2 | 15 |  |
Positive anti-SSB/La Ab | 1 (5.0%) | 19 (14.6%) | 0.410 |
 Missing | 2 | 15 |  |
Positive antiphospholipid Ab | 4 (26.7%) | 39 (31.0%) | 0.965 |
 Missing | 7 | 19 |  |
Low complement level | 14 (63.6%) | 81 (56.6%) | 0.537 |
 Missing | 0 | 2 |  |
Glucocorticoids | 22 (100.0%) | 128 (88.3%) | 0.188 |
 Dosage > 15 | 6/22 (27.3%) | 27/127 (21.3%) | 0.727 |
Hydroxychloroquine | 15 (68.2%) | 94 (64.8%) | 0.758 |
LMWH | 4 (18.2%) | 26 (17.9%) | 1.000 |
Aspirin | 5 (22.7%) | 43 (29.7%) | 0.503 |